Skip to main
BNTX
BNTX logo

BioNTech SE (BNTX) Stock Forecast & Price Target

BioNTech SE (BNTX) Analyst Ratings

Based on 22 analyst ratings
Buy
Strong Buy 55%
Buy 27%
Hold 18%
Sell 0%
Strong Sell 0%

Bulls say

BioNTech's fourth-quarter revenues of €1,190 million aligned with consensus estimates, driven by seasonally higher COVID vaccine sales, which are projected to support the company's revenue guidance of €1,700-€2,200 million for fiscal year 2025. The acquisition of Biotheus significantly enhances BioNTech's oncology portfolio, providing the company with a broader range of therapeutic options and reinforcing its position in the oncology market. With a promising and data-rich pipeline scheduled for 2025, including expectations for positive results from ongoing clinical trials in small cell lung cancer, BioNTech is well-positioned for long-term growth and value creation in its core oncology focus.

Bears say

The financial outlook for BioNTech appears negative due to anticipated manufacturing capacity limitations for personalized therapeutics, which may result in delayed revenue generation and adversely affect forecasts. Several risks, including potential negative data for multiple drug candidates, lower-than-expected market adoption, regulatory challenges, and competitive pressures from alternative treatment options, could further hinder the company's financial performance. Additionally, the uncertainty surrounding commercial partnerships and the possibility of adverse events associated with its therapeutic products contribute to a precarious situation for future revenue stability.

BioNTech SE (BNTX) has been analyzed by 22 analysts, with a consensus rating of Buy. 55% of analysts recommend a Strong Buy, 27% recommend Buy, 18% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BioNTech SE and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BioNTech SE (BNTX) Forecast

Analysts have given BioNTech SE (BNTX) a Buy based on their latest research and market trends.

According to 22 analysts, BioNTech SE (BNTX) has a Buy consensus rating as of Jul 1, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $147.70, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $147.70, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BioNTech SE (BNTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.